In last trading session, Avidity Biosciences Inc (NASDAQ:RNA) saw 2.43 million shares changing hands with its beta currently measuring 0.92. Company’s recent per share price level of $33.53 trading at $1.83 or 5.77% at ring of the bell on the day assigns it a market valuation of $4.04B. That closing price of RNA’s stock is at a discount of -67.01% from its 52-week high price of $56.00 and is indicating a premium of 35.85% from its 52-week low price of $21.51. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.25 million shares which gives us an average trading volume of 1.54 million if we extend that period to 3-months.
For Avidity Biosciences Inc (RNA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Upright in the green during last session for gaining 5.77%, in the last five days RNA remained trading in the green while hitting it’s week-highest on Monday, 07/14/25 when the stock touched $33.53 price level, adding 4.99% to its value on the day. Avidity Biosciences Inc’s shares saw a change of -25.16% in year-to-date performance and have moved 7.23% in past 5-day. Avidity Biosciences Inc (NASDAQ:RNA) showed a performance of 6.89% in past 30-days. Number of shares sold short was 16.34 million shares which calculate 11.56 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 70 to the stock, which implies a rise of 52.1% to its current value. Analysts have been projecting 70 as a low price target for the stock while placing it at a high target of 70. It follows that stock’s current price would drop -108.77% in reaching the projected high whereas dropping to the targeted low would mean a loss of -108.77% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -34.37% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -36.47% while estimates for its earnings growth in next 5 years are of -5.13%.
Avidity Biosciences Inc (NASDAQ:RNA)’s Major holders
Insiders are in possession of 5.17% of company’s total shares while institution are holding 112.41 percent of that, with stock having share float percentage of 118.54%. Investors also watch the number of corporate investors in a company very closely, which is 112.41% institutions for Avidity Biosciences Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at RNA for having 16.16 million shares of worth $660.1 million. And as of 2024-06-30, it was holding 15.1121 of the company’s outstanding shares.
The second largest institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, which was holding about 10.92 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.2093 of outstanding shares, having a total worth of $445.94 million.
On the other hand, T. Rowe Price New Horizons Fund, Inc. and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 4.43 shares of worth $148.7 million or 3.68% of the total outstanding shares. The later fund manager was in possession of 3.74 shares on May 31, 2025 , making its stake of worth around $125.39 million in the company or a holder of 3.10% of company’s stock.
